Alliance for Treatment of HPV Infections

The partners in a project to identify and biochemically validate novel targets for the prevention and treatment of human papillomavirus (HPV) infections have announced significant progress. Boehringer Ingelheim (Germany) and GPC Biotech (Boston, MA, USA) revealed that two research milestones have been achieved. This was accomplished by applying GPC Biotech's integrated genomics, proteomics, and cell biology technology platform.

Under the multi-year alliance, announced in January 2001, GPC Biotech is using its integrated technology platform to identify and biochemically validate novel targets and their molecular pathways associated with high and low risk HPV infections for Boehringer Ingelheim. The identified targets are validated by GPC Biotech to prove interaction in mammalian cells using cell biology technologies.

Prof. Dr. Bernd Wetzel, head of corporate division research and nonclinical development at Boehringer Ingelheim, commented: "We are extremely pleased with the quality and speed of the results achieved by GPC Biotech in our research alliance. The targets we have received so far already represent an important step forward in our effort to identify novel protein-protein interactions and cellular pathways for unique therapeutic interventions in HPV-related diseases.”





Related Links:
Boehringer
GPC Biotech